#USA #New York #securities lawsuit #Levi Korsinsky #Zenas BioPharma

Zenas BioPharma, Inc. Sued for Securities Law Violations

Zenas BioPharma, Inc., a company recently public on the NASDAQ under the ticker symbol ZBIO, has found itself embroiled in a securities class action lawsuit. This legal development has sent ripples through the investment community, prompting many shareholders to reevaluate their positions and legal standing. The lawsuit, announced by the prominent law firm Levi & Korsinsky, LLP, alleges that the company made false statements, exaggerated its financial capabilities, and misled investors regarding its operational funding.

Overview of the Lawsuit

The class action lawsuit is aimed at recovering losses for investors who purchased or acquired Zenas BioPharma securities around the time of its initial public offering (IPO) in September 2024. Allegations claim that the company overstated its financial position, specifically the duration it could maintain operations with existing resources and proceeds expected from the IPO. This misrepresentation, according to the lawsuit, left investors misinformed about the company's actual financial health leading up to and after the IPO.

Investors who feel negatively impacted by these developments are encouraged to take action promptly; they have until June 16, 2025, to seek lead plaintiff status in the case. Moving quickly can ensure their voices are heard and may enable them to participate in any potential recovery resulting from the lawsuit.

Details for Interested Investors

If you've experienced losses related to Zenas BioPharma's securities, it's vital to understand your rights. Those affected are urged to reach out to Levi & Korsinsky, where attorneys are prepared to assist in navigating the complexities of securities litigation. Importantly, there are no upfront costs for class members looking to join this lawsuit, making it accessible for individuals eager to seek redress.

Joseph E. Levi, Esq., one of the firm's leading attorneys, highlighted that investors do not need to serve as lead plaintiffs to be eligible for any recovery. This means that if you’ve been adversely affected, your participation in the class could still lead to potential compensation without incurring legal fees.

Firm's Reputation

Levi & Korsinsky has built a solid reputation over the last two decades, securing hundreds of millions for disgruntled shareholders and successfully managing high-profile securities cases. Their team of over 70 experienced legal professionals works diligently to represent investors. In fact, the firm has consistently ranked among the top 50 securities litigation firms in the U.S., affirming its expertise in handling complex cases.

Next Steps for Investors

For investors considering their options, detailed information regarding the lawsuit can be found on the firm's website or by contacting their offices directly. Interested parties can also fill out a submission form to be contacted by a representative. The time-sensitive nature of this opportunity has brought urgency to the situation, making it imperative for affected parties to act soon.

Conclusion

As Zenas BioPharma navigates this legal challenge, investors are reminded of the importance of understanding their rights, especially in the face of potential securities fraud. The class action lawsuit offers a mechanism for recovering losses and highlights the necessity for transparency in financial communications by publicly traded entities. If you have stakes in Zenas BioPharma and have suffered losses, don't delay in seeking legal advice to explore your options.

For more information, contact Levi & Korsinsky at [email protected] or by phone at (212) 363-7500. Stay informed and protect your investment interests during these challenging times.